• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of annrheumdAnnals of the Rheumatic DiseasesCurrent TOCInstructions for authors
Ann Rheum Dis. Jun 2001; 60(6): 592–598.
PMCID: PMC1753669

European multicentre study to define disease activity criteria for systemic sclerosis.* II. Identification of disease activity variables and development of preliminary activity indexes

Abstract

OBJECTIVE—To develop criteria for disease activity in systemic sclerosis (SSc) that are valid, reliable, and easy to use.
METHODS—Investigators from 19 European centres completed a standardised clinical chart for a consecutive number of patients with SSc. Three protocol management members blindly evaluated each chart and assigned a disease activity score on a semiquantitative scale of 0-10. Two of them, in addition, gave a blinded, qualitative evaluation of disease activity ("inactive to moderately active" or "active to very active" disease). Both these evaluations were found to be reliable. A final disease activity score and qualitative evaluation of disease activity were arrived at by consensus for each patient; the former represented the gold standard for subsequent analyses. The correlations between individual items in the chart and this gold standard were then analysed.
RESULTS—A total of 290 patients with SSc (117 with diffuse SSc (dSSc) and 173 with limited SSc (lSSc)) were enrolled in the study. The items (including Δ-factors—that is, worsening according to the patient report) that were found to correlate with the gold standard on multiple regression were used to construct three separate 10-point indices of disease activity: (a) Δ-cardiopulmonary (4.0), Δ-skin (3.0), Δ-vascular (2.0), and Δ-articular/muscular (1.0) for patients with dSSc; (b) Δ-skin (2.5), erythrocyte sedimentation rate (ESR) >30 mm/1st h (2.5), Δ-cardiopulmonary (1.5), Δ-vascular (1.0), arthritis (1.0), hypocomplementaemia (1.0), and scleredema (0.5) for lSSc; (c) Δ-cardiopulmonary (2.0), Δ-skin (2.0), ESR >30 mm/1st h (1.5), total skin score >20 (1.0), hypocomplementaemia (1.0), scleredema (0.5), digital necrosis (0.5), Δ-vascular (0.5), arthritis (0.5), TLCO <80% (0.5) for all patients with SSc. The three indexes were validated by the jackknife technique. Finally, receiver operating characteristic curves were constructed in order to define the value of the index with the best discriminant capacity for "active to very active" patients.
CONCLUSIONS—Three feasible, reliable, and valid preliminary indices to define disease activity in SSc were constructed.

Full Text

The Full Text of this article is available as a PDF (150K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Fries JF, Hochberg MC, Medsger TA, Jr, Hunder GG, Bombardier C. Criteria for rheumatic disease. Different types and different functions. The American College of Rheumatology Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1994 Apr;37(4):454–462. [PubMed]
  • Symmons DP. Disease assessment indices: activity, damage and severity. Baillieres Clin Rheumatol. 1995 May;9(2):267–285. [PubMed]
  • Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980 May;23(5):581–590. [PubMed]
  • Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol. 1986 Oct;13(5):911–916. [PubMed]
  • LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Jr, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988 Feb;15(2):202–205. [PubMed]
  • Hughes P, Gelsthorpe K, Doughty RW, Rowell NR, Rosenthal FD, Sneddon IB. The association of HLA-B8 with visceral disease in systemic sclerosis. Clin Exp Immunol. 1978 Mar;31(3):351–356. [PMC free article] [PubMed]
  • Casas JA, Subauste CP, Alarcón GS. A new promising treatment in systemic sclerosis: 5-fluorouracil. Ann Rheum Dis. 1987 Oct;46(10):763–767. [PMC free article] [PubMed]
  • Levesque H, Baudot N, Delpech B, Vayssairat M, Gancel A, Lauret P, Courtois H. Clinical correlations and prognosis based on hyaluronic acid serum levels in patients with progressive systemic sclerosis. Br J Dermatol. 1991 May;124(5):423–428. [PubMed]
  • Medsger TA, Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, Harris CA, Jablonska S, Jayson MI, Jimenez SA, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol. 1999 Oct;26(10):2159–2167. [PubMed]
  • Black CM, McWhirter A, Harrison NK, Kirk JM, Laurent GJ. Serum type III procollagen peptide concentrations in systemic sclerosis and Raynaud's phenomenon: relationship to disease activity and duration. Br J Rheumatol. 1989 Apr;28(2):98–103. [PubMed]
  • Degiannis D, Seibold JR, Czarnecki M, Raskova J, Raska K., Jr Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations. Arthritis Rheum. 1990 Mar;33(3):375–380. [PubMed]
  • Fiocco U, Rosada M, Cozzi L, Ortolani C, De Silvestro G, Ruffatti A, Cozzi E, Gallo C, Todesco S. Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity. Ann Rheum Dis. 1993 Apr;52(4):272–277. [PMC free article] [PubMed]
  • Patrick MR, Kirkham BW, Graham M, Harrision LC. Circulating interleukin 1 beta and soluble interleukin 2 receptor: evaluation as markers of disease activity in scleroderma. J Rheumatol. 1995 Apr;22(4):654–658. [PubMed]
  • Gruschwitz MS, Hornstein OP, von Den Driesch P. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum. 1995 Feb;38(2):184–189. [PubMed]
  • van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996 Apr;35(4):364–372. [PubMed]
  • Kahaleh MB, Sultany GL, Smith EA, Huffstutter JE, Loadholt CB, LeRoy EC. A modified scleroderma skin scoring method. Clin Exp Rheumatol. 1986 Oct-Dec;4(4):367–369. [PubMed]
  • Felson DT, Anderson JJ. Methodological and statistical approaches to criteria development in rheumatic diseases. Baillieres Clin Rheumatol. 1995 May;9(2):253–266. [PubMed]
  • Brennan P, Silman A. Statistical methods for assessing observer variability in clinical measures. BMJ. 1992 Jun 6;304(6840):1491–1494. [PMC free article] [PubMed]
  • Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, Neri R, Bombardieri S. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol. 1992 Sep-Oct;10(5):541–547. [PubMed]
  • Liang MH, Socher SA, Roberts WN, Esdaile JM. Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum. 1988 Jul;31(7):817–825. [PubMed]
  • Scott DL, Panayi GS, van Riel PL, Smolen J, van de Putte LB. Disease activity in rheumatoid arthritis: preliminary report of the Consensus Study Group of the European Workshop for Rheumatology Research. Clin Exp Rheumatol. 1992 Sep-Oct;10(5):521–525. [PubMed]
  • Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993 Jun;36(6):729–740. [PubMed]
  • LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am. 1996 Nov;22(4):675–694. [PubMed]
  • Belch JJ, Hickman P. Leukocyte activation and toxic oxygen metabolites/free radicals. Adv Exp Med Biol. 1997;428:1–5. [PubMed]
  • Seibold JR, Medsger TA, Jr, Winkelstein A, Kelly RH, Rodnan GP. Immune complexes in progressive systemic sclerosis (scleroderma). Arthritis Rheum. 1982 Oct;25(10):1167–1173. [PubMed]
  • Benbassat C, Schlesinger M, Luderschmidt C, Valentini G, Tirri G, Shoenfeld Y. The complement system and systemic sclerosis. Immunol Res. 1993;12(3):312–316. [PubMed]
  • Boers M, Tugwell P. OMERACT conference questionnaire results. OMERACT Committee. J Rheumatol. 1993 Mar;20(3):552–554. [PubMed]

Figures and Tables

Figure 1
Receiver operating characteristic curves showing the relation between the value of the calculated activity index and the presence of active or very active disease in (A) SSc whole series; (B) dSSc; (C) lSSc. AUC = area under the curve. ...

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...